Exact Sciences Corp
EXAS101.560USD
-0.340-0.33%
終値 12/31, 16:00（ET）15分遅れの株価
19.24B時価総額
損失額直近12ヶ月PER
詳細情報 Exact Sciences Corp 企業名
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Exact Sciences Corpの企業情報
企業コードEXAS
会社名Exact Sciences Corp
上場日Jan 30, 2001
最高経営責任者「CEO」Conroy (Kevin T)
従業員数6900
証券種類Ordinary Share
決算期末Jan 30
本社所在地5505 Endeavor Lane
都市MADISON
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号53719
電話番号16082845700
ウェブサイトhttps://www.exactsciences.com/
企業コードEXAS
上場日Jan 30, 2001
最高経営責任者「CEO」Conroy (Kevin T)
Exact Sciences Corpの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.14M
-20.54%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
60.76K
-16.49%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+18.67%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
28.90K
+22.97%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
23.04K
-11.04%
Ms. Leslie L. Trigg
Ms. Leslie L. Trigg
Independent Director
Independent Director
17.17K
+80.75%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
16.38K
+156.47%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
13.84K
--
Mr. Michael J. (Mike) Barber, M.D.
Mr. Michael J. (Mike) Barber, M.D.
Independent Director
Independent Director
13.14K
+121.18%
Mr. James E. Doyle
Mr. James E. Doyle
Lead Independent Director
Lead Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.14M
-20.54%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
60.76K
-16.49%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+18.67%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
28.90K
+22.97%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
23.04K
-11.04%
Ms. Leslie L. Trigg
Ms. Leslie L. Trigg
Independent Director
Independent Director
17.17K
+80.75%
収益内訳
通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Commercial
387.50M
47.78%
Medicare Parts B & C
274.49M
33.84%
Other
93.84M
11.57%
International
55.26M
6.81%
地域別USD
会社名
収益
比率
United States (Country)
755.83M
93.19%
Outside of united states
55.26M
6.81%
事業別
地域別
事業別USD
会社名
収益
比率
Commercial
387.50M
47.78%
Medicare Parts B & C
274.49M
33.84%
Other
93.84M
11.57%
International
55.26M
6.81%
株主
更新時刻: Sun, Nov 16
更新時刻: Sun, Nov 16
株主統計
種類
株主統計
株主統計
比率
The Vanguard Group, Inc.
9.36%
Capital World Investors
8.51%
Fidelity Management & Research Company LLC
8.11%
BlackRock Institutional Trust Company, N.A.
3.77%
Wellington Management Company, LLP
2.81%
他の
67.45%
株主統計
株主統計
比率
The Vanguard Group, Inc.
9.36%
Capital World Investors
8.51%
Fidelity Management & Research Company LLC
8.11%
BlackRock Institutional Trust Company, N.A.
3.77%
Wellington Management Company, LLP
2.81%
他の
67.45%
種類
株主統計
比率
Investment Advisor
51.08%
Investment Advisor/Hedge Fund
27.76%
Hedge Fund
9.78%
Pension Fund
2.26%
Research Firm
2.00%
Individual Investor
0.91%
Private Equity
0.77%
Bank and Trust
0.59%
Sovereign Wealth Fund
0.48%
他の
4.37%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
1336
180.61M
95.18%
-13.94M
2025Q3
1352
180.95M
106.13%
-112.86K
2025Q2
1416
180.92M
107.16%
-6.42M
2025Q1
1400
186.11M
105.23%
-12.34M
2024Q4
1391
186.68M
107.44%
-1.15M
2024Q3
1351
188.95M
104.99%
+4.63M
2024Q2
1335
183.23M
95.81%
+15.73M
2024Q1
1330
166.64M
95.05%
-5.91M
2023Q4
1339
163.38M
96.52%
-2.83M
2023Q3
1319
166.02M
95.28%
+1.45M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
The Vanguard Group, Inc.
17.76M
9.36%
-101.97K
-0.57%
Sep 30, 2025
Capital World Investors
16.14M
8.51%
-2.06M
-11.31%
Sep 30, 2025
Fidelity Management & Research Company LLC
15.38M
8.11%
-7.90M
-33.94%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
7.15M
3.77%
+116.86K
+1.66%
Sep 30, 2025
Wellington Management Company, LLP
5.33M
2.81%
-6.68M
-55.63%
Sep 30, 2025
State Street Investment Management (US)
5.20M
2.74%
-183.75K
-3.42%
Sep 30, 2025
Citadel Advisors LLC
3.94M
2.08%
+3.51M
+805.07%
Sep 30, 2025
MFS Investment Management
3.82M
2.01%
+855.10K
+28.85%
Sep 30, 2025
Columbia Threadneedle Investments (US)
3.73M
1.96%
+3.35M
+899.61%
Sep 30, 2025
Geode Capital Management, L.L.C.
3.31M
1.75%
+74.79K
+2.31%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
First Trust Nasdaq Lux Digi Health Solutions ETF
4.48%
Invesco Biotechnology & Genome ETF
3.72%
First Trust NYSE Arca Biotechnology Index Fund
3.72%
Alger Mid Cap 40 ETF
3.61%
Clough Select Equity ETF
3.13%
Clough Hedged Equity ETF
2.78%
iShares Health Innovation Active ETF
2.72%
State Street SPDR S&P Biotech ETF
2.32%
First Trust Indxx Medical Devices ETF
2.22%
ROBO Global Healthcare Technology & Innovation ETF
2.03%
詳細を見る
First Trust Nasdaq Lux Digi Health Solutions ETF
比率4.48%
Invesco Biotechnology & Genome ETF
比率3.72%
First Trust NYSE Arca Biotechnology Index Fund
比率3.72%
Alger Mid Cap 40 ETF
比率3.61%
Clough Select Equity ETF
比率3.13%
Clough Hedged Equity ETF
比率2.78%
iShares Health Innovation Active ETF
比率2.72%
State Street SPDR S&P Biotech ETF
比率2.32%
First Trust Indxx Medical Devices ETF
比率2.22%
ROBO Global Healthcare Technology & Innovation ETF
比率2.03%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
よくある質問
Exact Sciences Corpの上位5名の株主は誰ですか？
Exact Sciences Corpの上位5名の株主は以下のとおりです。
The Vanguard Group, Inc.は17.76M株を保有しており、これは全体の9.36%に相当します。
Capital World Investorsは16.14M株を保有しており、これは全体の8.51%に相当します。
Fidelity Management & Research Company LLCは15.38M株を保有しており、これは全体の8.11%に相当します。
BlackRock Institutional Trust Company, N.A.は7.15M株を保有しており、これは全体の3.77%に相当します。
Wellington Management Company, LLPは5.33M株を保有しており、これは全体の2.81%に相当します。
The Vanguard Group, Inc.は17.76M株を保有しており、これは全体の9.36%に相当します。
Capital World Investorsは16.14M株を保有しており、これは全体の8.51%に相当します。
Fidelity Management & Research Company LLCは15.38M株を保有しており、これは全体の8.11%に相当します。
BlackRock Institutional Trust Company, N.A.は7.15M株を保有しており、これは全体の3.77%に相当します。
Wellington Management Company, LLPは5.33M株を保有しており、これは全体の2.81%に相当します。
Exact Sciences Corpの株主タイプ上位3種は何ですか？
Exact Sciences Corpの株主タイプ上位3種は、
The Vanguard Group, Inc.
Capital World Investors
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
Capital World Investors
Fidelity Management & Research Company LLC
Exact Sciences Corp（EXAS）の株式を保有している機関の数はいくつですか？
2025Q4時点で、Exact Sciences Corpの株式を保有している機関は1336社あり、保有株式の総市場価値は約180.61Mで、全体の95.18%を占めています。2025Q3と比較して、機関の持ち株は-10.95%増加しています。
Exact Sciences Corpの最大の収益源は何ですか？
FY2025Q2において、Commercial部門がExact Sciences Corpにとって最大の収益を生み出しており、その金額は387.50Mで、全収益の47.78%を占めています。
